

Michael J Cork

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9301736/publications.pdf>

Version: 2024-02-01

126
papers

7,946
citations

81900

39
h-index

51608

86
g-index

142
all docs

142
docs citations

142
times ranked

5921
citing authors

#	ARTICLE	IF	CITATIONS
1	Vehicles for atopic dermatitis therapies: more than just a placebo. <i>Journal of Dermatological Treatment</i> , 2022, 33, 685-698.	2.2	21
2	Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 422-433.	2.4	22
3	Proposal of 0.5Âµg of protein/100Âµg of processed food as threshold for voluntary declaration of food allergen traces in processed foodâ€”A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GAÂ²LEN position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1736-1750.	5.7	21
4	Randomized controlled pilot trial with ionâ€”exchange water softeners to prevent eczema (SOFTER) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.9	10
5	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitisâ€”A pooled analysis of trial data. <i>Pediatric Dermatology</i> , 2022, 39, 187-196.	0.9	23
6	Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1154-1164.	1.3	15
7	Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczemaâ€”prone skin*. <i>British Journal of Dermatology</i> , 2022, 186, 875-886.	1.5	24
8	Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. <i>JID Innovations</i> , 2022, 2, 100131.	2.4	66
9	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). <i>American Journal of Clinical Dermatology</i> , 2022, 23, 365-383.	6.7	30
10	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. <i>British Journal of Dermatology</i> , 2021, 184, 437-449.	1.5	289
11	The effect of water hardness on atopic eczema, skin barrier function: A systematic review, meta-analysis. <i>Clinical and Experimental Allergy</i> , 2021, 51, 430-451.	2.9	15
12	Dupilumab provides favourable long-term safety and efficacy in children aged 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. <i>British Journal of Dermatology</i> , 2021, 184, 857-870.	1.5	45
13	Skin care interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2021, CD013534.	2.8	37
14	Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB156.	2.9	0
15	Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta-analysis. <i>Clinical and Experimental Allergy</i> , 2021, 51, 402-418.	2.9	38
16	Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With Comorbid Allergic Rhinitis or Asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB28.	2.9	0
17	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	2.4	27
18	484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. <i>Journal of Investigative Dermatology</i> , 2021, 141, S84.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Imaging striae distensae: a comparison between PS-OCT and digital dermoscopy. Biomedical Optics Express, 2021, 12, 3296.	2.9	3
20	A Predictive Self-Organizing Multicellular Computational Model of Infant Skin Permeability to Topically Applied Substances. Journal of Investigative Dermatology, 2021, 141, 2049-2055.e1.	0.7	6
21	Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatric Drugs, 2021, 23, 515-527.	3.1	15
22	27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial. Journal of the American Academy of Dermatology, 2021, 85, AB141.	1.2	0
23	26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY) in children with atopic dermatitis (AD). Journal of the American Academy of Dermatology, 2021, 85, AB120.	1.2	0
24	26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). Journal of the American Academy of Dermatology, 2021, 85, AB120.	1.2	0
25	27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD). Journal of the American Academy of Dermatology, 2021, 85, AB136.	1.2	0
26	26304 Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. Journal of the American Academy of Dermatology, 2021, 85, AB97.	1.2	0
27	Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities. Allergy and Asthma Proceedings, 2021, 42, 425-431.	2.2	4
28	Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis. SKIN the Journal of Cutaneous Medicine, 2021, 5, s9.	0.3	1
29	Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis, 2021, 32, S81-S91.	1.6	7
30	Response to: Letter to the Editor Regarding "An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-Vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1". Dermatology and Therapy, 2021, 11, 2249-2252.	3.0	0
31	161...52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE). , 2021, , .		0
32	P193 DUPILUMAB DECREASES TOTAL AND ALLERGEN-SPECIFIC IGE IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD). Annals of Allergy, Asthma and Immunology, 2021, 127, S54-S55.	1.0	1
33	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. Dermatology and Therapy, 2021, 11, 1643-1656.	3.0	1
34	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment, 2020, 31, 606-614.	2.2	72
35	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase II open-label trial and subsequent phase III open-label extension. British Journal of Dermatology, 2020, 182, 85-96.	1.5	111
36	Atopic dermatitis epidemiology and unmet need in the United Kingdom. Journal of Dermatological Treatment, 2020, 31, 801-809.	2.2	43

#	ARTICLE	IF	CITATIONS
37	Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior. <i>Pediatric Dermatology</i> , 2020, 37, 130-136.	0.9	34
38	P302 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT FOOD ALLERGIES. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, S40-S41.	1.0	0
39	Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 255-266.	13.7	273
40	An Investigation of the Skin Barrier Restoring Effects of a Cream and Lotion Containing Ceramides in a Multi-vesicular Emulsion in People with Dry, Eczema-Prone, Skin: The RESTORE Study Phase 1. <i>Dermatology and Therapy</i> , 2020, 10, 1031-1041.	3.0	17
41	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
42	15413 Dupilumab improves signs and symptoms in adult and adolescent patients with erythrodermic atopic dermatitis: A pooled subgroup analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB39.	1.2	0
43	16818 An investigation of the skin barrier restoring effects of a cream containing ceramides in a multivesicular emulsion in people with dry, eczema-prone, skin: The RESTORE study phase 2. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB71.	1.2	0
44	455 Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis. <i>Journal of Investigative Dermatology</i> , 2020, 140, S60.	0.7	0
45	Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1499-1501.	1.2	3
46	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e839-e842.	2.4	22
47	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	2.4	99
48	Skincare interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2020, , .	2.8	7
49	Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. <i>Lancet</i> , The, 2020, 395, 962-972.	13.7	178
50	A study of dupilumab in the treatment of adolescents with eczema. <i>British Journal of Dermatology</i> , 2020, 182, e30-e30.	1.5	0
51	ä,éíâ...³äž dupilumab æ²»ç—æ¹¿ç—¹é¹°á¹æ,èè...çš„ç”ç©¶. <i>British Journal of Dermatology</i> , 2020, 182, e47-e47.		6
52	605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. <i>Journal of Investigative Dermatology</i> , 2019, 139, S104.	0.7	1
53	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy â€“ international eczema council survey and opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1224-1231.	2.4	50
54	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council surveyâ€“based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	2.4	15

#	ARTICLE	IF	CITATIONS
55	Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. <i>BMJ Open</i> , 2019, 9, e027168.	1.9	8
56	The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects. <i>Journal of Investigative Dermatology</i> , 2018, 138, 68-77.	0.7	54
57	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, 1083-1101.	1.5	380
58	æœåĈÉ²â•æš—ç»“â•ã¼/4 éšæœšâ±œÉf“çš®è“ç±»â•ºé††æ²»ç—â•¹çžžâçç’Aâº”ç”â,â.....â^tæ^—â,èœâ—æ^—èœ...âœ”âĈ»âĵ,šââ»ºè®®é††		
59	Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography. <i>Biomedical Optics Express</i> , 2018, 9, 2001.	2.9	24
60	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, e366-e366.	1.5	2
61	Infant Skin Barrier, Structure, and Enzymatic Activity Differ from Those of Adult in an East Asian Cohort. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	11
62	pH in Atopic Dermatitis. <i>Current Problems in Dermatology</i> , 2018, 54, 95-107.	0.7	39
63	Computational design of treatment strategies for proactive therapy on atopic dermatitis using optimal control theory. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2017, 375, 20160285.	3.4	17
64	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 623-633.	1.2	170
65	Comparison of the Simple Patient-Centric Atopic Dermatitis Scoring System PEST with SCORAD in Young Children Using a Ceramide Dominant Therapeutic Moisturizer. <i>Dermatology and Therapy</i> , 2017, 7, 383-393.	3.0	6
66	P479 Dupilumab improves patient-reported outcomes in atopic dermatitis patients inadequately controlled, intolerant, or inadvisable for cyclosporine-A. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, S94-S95.	1.0	1
67	The British Skin Foundation: 20 years of supporting dermatology research. <i>British Journal of Dermatology</i> , 2017, 177, 608-609.	1.5	0
68	Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 343.	1.6	56
69	Development of stratum corneum chymotrypsin-like protease activity and natural moisturizing factors from birth to 4 weeks of age compared with adults. <i>British Journal of Dermatology</i> , 2016, 175, 713-720.	1.5	18
70	A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. <i>British Journal of Dermatology</i> , 2016, 175, 1011-1019.	1.5	39
71	The Effect of an Emollient Containing Urea, Ceramide NP, and Lactate on Skin Barrier Structure and Function in Older People with Dry Skin. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 135-147.	2.5	58
72	Recommendations from a European Roundtable Meeting on Best Practice Healthy Infant Skin Care. <i>Pediatric Dermatology</i> , 2016, 33, 311-321.	0.9	98

#	ARTICLE	IF	CITATIONS
73	Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1715-1719.e4.	2.9	22
74	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
75	The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. <i>British Journal of Dermatology</i> , 2014, 170, 914-921.	1.5	63
76	Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 818-823.	2.9	594
77	Topical oils for the prevention or treatment of dry skin in term infants. <i>The Cochrane Library</i> , 2014, , .	2.8	2
78	Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings. <i>The Cochrane Library</i> , 2014, , .	2.8	9
79	Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. <i>BMC Dermatology</i> , 2013, 13, 7.	2.1	31
80	Topical treatments for chronic plaque psoriasis: An abridged Cochrane Systematic Review. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 799-807.	1.2	51
81	The effects of pimecrolimus on the innate immune response in atopic dermatitis. <i>British Journal of Dermatology</i> , 2013, 168, 235-236.	1.5	5
82	Optical coherence tomography demonstrates differential epidermal thinning of human forearm volar skin after 2 weeks application of a topical corticosteroid vs a non-steroidal anti-inflammatory alternative. , 2013, , .		0
83	Effect of Olive and Sunflower Seed Oil on the Adult Skin Barrier: Implications for Neonatal Skin Care. <i>Pediatric Dermatology</i> , 2013, 30, 42-50.	0.9	145
84	Topical treatments for chronic plaque psoriasis. <i>The Cochrane Library</i> , 2013, , CD005028.	2.8	90
85	Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. <i>British Journal of Dermatology</i> , 2013, 169, 519-527.	1.5	44
86	Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2013, 42, 203-214.	0.5	46
87	Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial. <i>BMC Pediatrics</i> , 2012, 12, 59.	1.7	61
88	The Challenges and Realities of Diaper Area Cleansing for Parents. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2012, 41, E13-E25.	0.5	22
89	Use of oil for baby skincare: A survey of UK maternity and neonatal units. <i>British Journal of Midwifery</i> , 2011, 19, 354-362.	0.4	25
90	Aqueous cream damages the skin barrier. <i>British Journal of Dermatology</i> , 2011, 164, 1179-1180.	1.5	18

#	ARTICLE	IF	CITATIONS
91	The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. <i>British Journal of Dermatology</i> , 2011, 165, 329-334.	1.5	73
92	Patient education about topical treatments. <i>British Journal of Dermatology</i> , 2011, 165, 1159-1160.	1.5	4
93	Infant skin-cleansing product versus water: A pilot randomized, assessor-blinded controlled trial. <i>BMC Pediatrics</i> , 2011, 11, 35.	1.7	37
94	Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. <i>Dermatology</i> , 2011, 222, 36-48.	2.1	20
95	Skin barrier breakdown: a renaissance in emollient therapy. <i>British Journal of Nursing</i> , 2009, 18, 872-877.	0.7	74
96	British Society for Paediatric Dermatology. <i>British Journal of Dermatology</i> , 2009, 161, 115-127.	1.5	16
97	Epidermal Barrier Dysfunction in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1892-1908.	0.7	612
98	Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 751-759.	2.4	101
99	Topical treatments for chronic plaque psoriasis. , 2009, , CD005028.		43
100	Skin Barrier Dysfunction in Atopic Dermatitis. <i>Basic and Clinical Dermatology</i> , 2009, , 211-240.	0.1	1
101	Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis. <i>British Journal of Dermatology</i> , 2008, 159, 77-85.	1.5	32
102	The autoimmune regulator gene (<i>AIRE</i>) is strongly associated with vitiligo. <i>British Journal of Dermatology</i> , 2008, 159, ???-???	1.5	54
103	Gene-environment interactions in atopic dermatitis. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e11-e31.	0.8	2
104	Epidermal barrier dysfunction in atopic dermatitis. <i>Series in Dermatological Treatment</i> , 2008, , 35-58.	0.1	2
105	New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 3-21.	2.9	465
106	Adverse effects of topical glucocorticosteroids. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1-15.	1.2	893
107	The development of a preference-based measure of health in children with atopic dermatitis. <i>British Journal of Dermatology</i> , 2005, 153, 372-377.	1.5	57
108	Predisposition to sensitive skin and atopic eczema. <i>Community Practitioner</i> , 2005, 78, 440-2.	0.1	7

#	ARTICLE	IF	CITATIONS
109	Genetic Association Between an AACC Insertion in the 3'UTR of the Stratum Corneum Chymotryptic Enzyme Gene and Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2004, 123, 62-66.	0.7	148
110	Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. <i>British Journal of Dermatology</i> , 2003, 149, 582-589.	1.5	227
111	Eumovate TM (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety. <i>Journal of Dermatological Treatment</i> , 2003, 14, 71-85.	2.2	4
112	Role of the Autoimmune Regulator (<i>AIRE</i>) gene in alopecia areata: Strong association of a potentially functional <i>AIRE</i> polymorphism with alopecia universalis. <i>Tissue Antigens</i> , 2002, 60, 489-495.	1.0	74
113	Topical preparations for the treatment of psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2002, 146, 351-364.	1.5	158
114	Association analysis of IL1A and IL1B variants in alopecia areata. <i>Heredity</i> , 2001, 87, 215-219.	2.6	19
115	Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. <i>British Journal of Dermatology</i> , 2000, 142, 52-58.	1.5	245
116	Topical preparations for the treatment of psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2000, 142, 351-364.	1.5	6
117	Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region. <i>Human Genetics</i> , 2000, 106, 639-645.	3.8	54
118	The importance of skin barrier function. <i>Journal of Dermatological Treatment</i> , 1997, 8, S7-S13.	2.2	102
119	Cytokine dermatosis: reactivation of eczema during interleukin-2 infusion. <i>British Journal of Dermatology</i> , 1997, 136, 644-645.	1.5	9
120	The role of in atopic eczema: treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1996, 7, S31-S37.	2.4	15
121	Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. <i>Human Genetics</i> , 1996, 97, 723-726.	3.8	17
122	Treatment of Grover's disease with calcipotriol (Dovonex [®]). <i>British Journal of Dermatology</i> , 1995, 132, 832-833.	1.5	26
123	Severity of Alopecia Areata Is Associated with a Polymorphism in the Interleukin-1 Receptor Antagonist Gene. <i>Journal of Investigative Dermatology</i> , 1994, 103, 387-390.	0.7	172
124	Cytokine gene activation across the advancing edge of psoriatic plaques. <i>Journal of Dermatological Science</i> , 1993, 6, 2.	1.9	0
125	Cytokine gene polymorphisms in inflammatory dermatoses. <i>Journal of Dermatological Science</i> , 1993, 6, 18.	1.9	0
126	A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris. <i>Journal of Dermatological Treatment</i> , 1993, 4, 119-122.	2.2	15